Imperial College London
Alternate

Dr Peter Kelleher

Faculty of Medicine, Department of Infectious Disease

Reader in Immunology
 
 
 
//

Contact

 

+44 (0)20 3315 8251p.kelleher

 
 
//

Location

 

J.2.10Chelsea and Westminster HospitalChelsea and Westminster Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Cocker:2019:10.1089/aid.2018.0176,
author = {Cocker, ATH and Greathead, L and Herasimtschuk, AA and Mandalia, S and Kelleher, P and Imami, N},
doi = {10.1089/aid.2018.0176},
journal = {AIDS Research and Human Retroviruses},
title = {Therapeutic immunisation benefits mucosal-associated invariant T-cell recovery in contrast to IL-2, GM-CSF, and rhGH addition in HIV-1+ treated patients: individual case reports from phase I trial},
url = {http://dx.doi.org/10.1089/aid.2018.0176},
volume = {35},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Mucosal-associated invariant T (MAIT) cell populations are reduced in frequency in HIV-1+ patients, and this disruption is associated with systemic immune activation. Reconstitution of MAIT frequency may benefit HIV-1-infected individuals; however, only recently has in vivo work been endeavored. Treatment with interleukin (IL)-2, granulocyte-macrophage colony-stimulating factor (GM-CSF), and recombinant human growth hormone (rhGH) immunotherapy combined with an HIV-1 vaccine in the context of antiretroviral therapy (ART) has shown to reconstitute CD4 T cell population numbers and function. In this study cryopreserved peripheral blood mononuclear cells (PBMCs) from 12 HIV-1+ patients who were undergoing a combination of HIV-1 vaccine and/or IL-2, GM-CSF and rhGH immunotherapy in conjunction with ART were analyzed to assess the potential of this treatment to promote MAIT cell proliferation. PBMCs were thawed from study baseline, weeks 2 and 48 time points, fluorescently stained for MAIT cell markers, and assessed by flow cytometric analysis. Matched pairs and intergroup results were statistically compared using appropriate methods. MAIT cell frequency was increased from baseline at 48 weeks in participants who received vaccine only, whereas individuals receiving IL-2, GM-CSF, and rhGH immunotherapy with or without vaccine did not show additional benefit. Although IL-2, GM-CSF, and rhGH treatment promotes CD4 T cell reconstitution and HIV-1-specific T cell function, it does not support MAIT cell recovery in patients on suppressive ART. Therapeutic immunization however has a positive effect, highlighting the importance of aiming for balanced promotion of T cell population reconstitution to impact on HIV-1 transmission and pathogenesis.
AU  - Cocker,ATH
AU  - Greathead,L
AU  - Herasimtschuk,AA
AU  - Mandalia,S
AU  - Kelleher,P
AU  - Imami,N
DO  - 10.1089/aid.2018.0176
PY  - 2019///
SN  - 0889-2229
TI  - Therapeutic immunisation benefits mucosal-associated invariant T-cell recovery in contrast to IL-2, GM-CSF, and rhGH addition in HIV-1+ treated patients: individual case reports from phase I trial
T2  - AIDS Research and Human Retroviruses
UR  - http://dx.doi.org/10.1089/aid.2018.0176
UR  - http://hdl.handle.net/10044/1/66925
VL  - 35
ER  -
Download